Overview

Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of quetiapine fumarate extended-release (XR) used as mono-therapy, administered once daily, in the treatment of schizophrenic patient with acute episode.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Chlorpromazine
Quetiapine Fumarate